Funding supports trial of TT-P34 as potential treatment
Teitur Trophics has raised €28 million (about $29.7 million) to advance its lead candidate, TT-P34, into a Phase 1b clinical trial as a possible treatment for Parkinson’s and other neurodegenerative diseases. “There is a pressing need for new therapies for neurodegenerative diseases which have a detrimental impact on…